Scholarlink

Background <p>Utility of repeated boosts of anti-SARS-CoV-2 vaccination in persons with MS (pwMS) treated with ocrelizumab is questioned.</p> Objective <p>Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.</p> Methods <p>Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.</p> Results <p>ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2&#xa0;years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8<sup>+</sup> T memory stem cells. CD8<sup>+</sup> T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.</p> Conclusions <p>Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • Lucia Moiola,
  • Alessandra Mandelli,
  • Maciej Tarkowski,
  • Annamaria Finardi,
  • Arianna Gabrieli,
  • Chiara Zanetta,
  • Vittorio Viti,
  • Irene Gattuso,
  • Federica Esposito,
  • Rosetta Pedotti,
  • Erwan Muros-Le Rouzic,
  • Catarina Raposo,
  • Maria A. Rocca,
  • Massimo Locatelli,
  • Chiara Bonini,
  • Roberto Furlan,
  • Agostino Riva,
  • Massimo Filippi

摘要

Background

Utility of repeated boosts of anti-SARS-CoV-2 vaccination in persons with MS (pwMS) treated with ocrelizumab is questioned.

Objective

Investigate antiviral antibody and T-cell responses after mRNA vaccination for SARS-CoV-2 in ocrelizumab-treated pwMS.

Methods

Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for IFN-γ detection, and by multiparametric flow cytometry analyses for assessment and characterization of T-cell activation. Anti-SARS-CoV-2 spike and nucleocapsid antibodies were analyzed in plasma of pwMS using two commercial platforms.

Results

ELISPOT assay against the spike protein of SARS-CoV-2 showed that COVID vaccination with mRNA results in the development of a robust specific T-cell reactivity that is sustained over repeated cycles of vaccination and tends to decline 2 years after last boost. Flow cytometry analysis following stimulation with SARS-CoV-2 peptide pools confirmed the presence of CD8+ T memory stem cells. CD8+ T memory stem cells, in particular, increased after repeated boosts of vaccination, as occurred for anti-SARS-CoV-2 antibodies.

Conclusions

Repeated cycles of vaccination increase T and B-cell reactivity against SARS-CoV-2.